Berenberg raises UCB stock price target to EUR290 on strong Bimzelx growth
PositiveFinancial Markets

Berenberg has raised its price target for UCB's stock to EUR290, driven by the impressive growth of Bimzelx, a treatment for psoriasis. This adjustment reflects confidence in UCB's potential and highlights the increasing demand for innovative therapies in the pharmaceutical market. Investors may see this as a positive sign for UCB's future performance, especially as Bimzelx continues to gain traction.
— Curated by the World Pulse Now AI Editorial System